To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
A phase 2 trial of Vismodegib in basal cell carcinoma, run by Stamford Pharmaceuticals, Inc., now recruiting.
Overview
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma is a phase 2 interventional study registered as NCT06344052 by Stamford Pharmaceuticals, Inc., with 80 participants planned, started 2024-04-09 and due to reach its primary completion in 2026-09-30. Interventions recorded: SP-002, Vismodegib. Conditions listed: Basal Cell Carcinoma. No results are recorded here; the registry entry is the source.
Setting
A Phase 2 Study to Assess the Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
Phase
Phase 2
Sponsor
Stamford Pharmaceuticals, Inc.
Registry
Enrolled
80
Similar pages
not linked directly; found by shared links- TechnologyHedgehog pathway inhibitors
Shares Vismodegib, Basal cell carcinoma.
- PathwayBasal cell carcinoma (KEGG map)
Shares Vismodegib, Basal cell carcinoma.
- TargetSmoothened (hedgehog pathway)
Shares Vismodegib, Basal cell carcinoma.
- CancerSkin cancer (all types)
Shares Vismodegib, Basal cell carcinoma.